1.Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. The New England journal of medicine. 2017;377(21):2063–72.
2.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
3.Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World journal of gastroenterology. 2014;20(2):475–85.
4.Agrawal RP, Sheroan V, Ola V, Sulemani AA, Singh N, Sirohi P, et al. Hepatocyte growth factor, adiponectin and hepatic histopathology in non-alcoholic steatohepatitis. The Journal of the Association of Physicians of India. 2013;61(11):789–92.
5.Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. Journal of gastroenterology and hepatology. 2011;26 Suppl 1:188–202.
6.Tojima H, Kakizaki S, Kosone T, Horiguchi N, Yamazaki Y, Sato K, et al. Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology international. 2012;6(3):620–30.
7.Kroy DC, Schumacher F, Ramadori P, Hatting M, Bergheim I, Gassler N, et al. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. J Hepatol. 2014;61(4):883–90.
8.Ma ZG, Lv XD, Zhan LL, Chen L, Zou QY, Xiang JQ, et al. Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymal stem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway. World journal of gastroenterology. 2016;22(6):2092–103.
9.Liao Y, Gong J, Zhou W, Dong H, Liang J, Luo M, et al. Serum liver fibrosis markers discriminate significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase. J Med Virol. 2019;91(4):642–9.
10.Barchetta I, Cimini FA, De Gioannis R, Ciccarelli G, Bertoccini L, Lenzi A, et al. Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. Diabetes/metabolism research and reviews. 2018;34(5):e2998.
11.Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(32):E2165–72.
12.Ripoche J. Blood platelets and inflammation: their relationship with liver and digestive diseases. Clinics and research in hepatology and gastroenterology. 2011;35(5):353–7.
13.Mege D, Aubert M, Lacroix R, Dignat-George F, Panicot-Dubois L, Dubois C. Involvement of Platelets in Cancers. Seminars in thrombosis and hemostasis. 2019;45(6):569–75.
14.Han S, Lee S, Yang JD, Leise MD, Ahn JH, Kim S, et al. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2018;24(1):44–55.
15.Ma X, Holalkere NS, Kambadakone RA, Mino-Kenudson M, Hahn PF, Sahani DV. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics: a review publication of the Radiological Society of North America, Inc. 2009;29(5):1253–77.
16.Cengiz M, Candir BA, Yilmaz G, Akyol G, Ozenirler S. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage? World journal of gastroenterology. 2013;19(42):7412–8.
17.Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Digestive diseases and sciences. 2015;60(11):3194–202.
18.Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–5.
19.Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management. Endocrine reviews. 2019.
20.Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL–6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. The Journal of clinical investigation. 1998;101(2):311–20.
21.Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. The Journal of biological chemistry. 1995;270(2):603–11.
22.Ilangumaran S, Villalobos-Hernandez A, Bobbala D, Ramanathan S. The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions. Cytokine. 2016;82:125–39.
23.Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293–302 e4.
24.Ding ZM, Xiao Y, Wu X, Zou H, Yang S, Shen Y, et al. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. Frontiers in pharmacology. 2018;9:410.
25.Hamza RT, Ahmed AY, Rezk DG, Hamed AI. Dietary fructose intake in obese children and adolescents: relation to procollagen type III N-terminal peptide (P3NP) and non-alcoholic fatty liver disease. Journal of pediatric endocrinology & metabolism: JPEM. 2016;29(12):1345–52.
26.Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PloS one. 2013;8(12):e82092.
27.Garjani A, Safaeiyan A, Khoshbaten M. Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepatitis monthly. 2015;15(1):e24449.
28.Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.
29.Watanabe M, Murata S, Hashimoto I, Nakano Y, Ikeda O, Aoyagi Y, et al. Platelets contribute to the reduction of liver fibrosis in mice. Journal of gastroenterology and hepatology. 2009;24(1):78–89.
30.Massoullie G, Sapin V, Ploux S, Rossignol P, Mulliez A, Jean F, et al. Low fibrosis biomarker levels predict cardiac resynchronization therapy response. Scientific reports. 2019;9(1):6103.
31.He S, Lei W, Li J, Yu K, Yu Y, Zhou L, et al. Relation of Platelet Parameters With Incident Cardiovascular Disease (The Dongfeng-Tongji Cohort Study). The American journal of cardiology. 2019;123(2):239–48.
32.Bell EJ, Decker PA, Tsai MY, Pankow JS, Hanson NQ, Wassel CL, et al. Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2018;272:162–7.
33.Kosone T, Takagi H, Horiguchi N, Ariyama Y, Otsuka T, Sohara N, et al. HGF ameliorates a high-fat diet-induced fatty liver. American journal of physiology Gastrointestinal and liver physiology. 2007;293(1):G204–10.
34.Dominguez-Perez M, Nuno-Lambarri N, Clavijo-Cornejo D, Luna-Lopez A, Souza V, Bucio L, et al. Hepatocyte Growth Factor Reduces Free Cholesterol-Mediated Lipotoxicity in Primary Hepatocytes by Countering Oxidative Stress. Oxidative medicine and cellular longevity. 2016;2016:7960386.
35.Fafalios A, Ma J, Tan X, Stoops J, Luo J, Defrances MC, et al. A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nature medicine. 2011;17(12):1577–84.
36.Quilliot D, Alla F, Bohme P, Bruntz JF, Hammadi M, Dousset B, et al. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. International journal of obesity. 2005;29(11):1321–8.
37.Fay WP. Linking inflammation and thrombosis: Role of C-reactive protein. World journal of cardiology. 2010;2(11):365–9.
38.Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. Correlation between mean platelet volume and blood glucose levels after oral glucose loading in normoglycemic and prediabetic Japanese subjects. Journal of diabetes investigation. 2014;5(1):66–71.
39.Gang L, Yanyan Z, Zhongwei Z, Juan D. Association between mean platelet volume and hypertension incidence. Hypertension research: official journal of the Japanese Society of Hypertension. 2017;40(8):779–84.